Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
6(67%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
2
22%
Ph phase_3
6
67%

Phase Distribution

1

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
6(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(3)

Detailed Status

Recruiting6
Completed3

Development Timeline

Analytics

Development Status

Total Trials
9
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 36 (66.7%)

Trials by Status

recruiting667%
completed333%

Recent Activity

6 active trials
Showing 5 of 9
completedphase_2

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

NCT04626505
recruitingphase_3

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281
recruitingphase_3

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

NCT07276282
recruitingphase_3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
recruitingphase_3

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04626505Phase 2

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

Completed
NCT06118281Phase 3

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Recruiting
NCT07276282Phase 3

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Recruiting
NCT05636176Phase 3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Recruiting
NCT06200207Phase 3

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Recruiting
NCT07301034Phase 3

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Recruiting
NCT03926117Phase 2

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Completed
NCT05379829Phase 1

A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

Completed
NCT06263244Phase 3

Specifying the Anti-inflammatory Effects of Ziltivekimab

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9